Literature DB >> 17190526

Neurotensin agonists: potential in the treatment of schizophrenia.

Mona Boules1, Amanda Shaw, Paul Fredrickson, Elliott Richelson.   

Abstract

Neurotensin (NT) is a neuropeptide that, for decades, has been implicated in the biology of schizophrenia. It is closely associated with, and is thought to modulate, dopaminergic and other neurotransmitter systems involved in the pathophysiology of various neuropsychiatric diseases, including schizophrenia. This review outlines the neurochemistry and function of the NT system and the data implicating its role in schizophrenia. The data suggest that NT receptor agonists have the potential to be used as novel therapeutic agents for the treatment of schizophrenia, with the added benefits of (i) not causing weight gain, an adverse effect that is problematic with some of the currently used atypical antipsychotic drugs; and (ii) helping patients to stop smoking, a behaviour that is highly prevalent in those with schizophrenia.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17190526     DOI： 10.2165/00023210-200721010-00002

Source DB:  PubMed          Journal:  CNS Drugs        ISSN： 1172-7047            Impact factor:   5.749


  149 in total

Review 1.  Distribution of neurotensin receptors in mammalian brain. What it is telling us about its interactions with other neurotransmitter systems.

Authors:  R Quirion; W B Rowe; P A Lapchak; D M Araujo; A Beaudet
Journal:  Ann N Y Acad Sci       Date:  1992       Impact factor: 5.691

2.  Endogenous neurotensin regulates hypothalamic-pituitary-adrenal axis activity and peptidergic neurons in the rat hypothalamic paraventricular nucleus.

Authors:  A Nicot; W B Rowe; E R De Kloet; C Betancur; D S Jessop; S L Lightman; R Quirion; W Rostène; A Bérod
Journal:  J Neuroendocrinol       Date:  1997-04       Impact factor: 3.627

3.  The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes.

Authors:  I Dubuc; J Costentin; J P Terranova; M C Barnouin; P Soubrié; G Le Fur; W Rostène; P Kitabgi
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

4.  Pro-dopamine effects of neurotensin on sensorimotor gating deficits.

Authors:  D Feifel; T L Reza; S L Robeck
Journal:  Peptides       Date:  1997       Impact factor: 3.750

Review 5.  The neuropathology of schizophrenia.

Authors:  S E Bachus; J E Kleinman
Journal:  J Clin Psychiatry       Date:  1996       Impact factor: 4.384

6.  Effects of neurotensin on midbrain dopamine neurons: are they mediated by formation of a neurotensin-dopamine complex?

Authors:  W X Shi; B S Bunney
Journal:  Synapse       Date:  1991-11       Impact factor: 2.562

Review 7.  Adrenal neuropeptides: regulation and interaction with ACTH and other adrenal regulators.

Authors:  E J Whitworth; O Kosti; D Renshaw; J P Hinson
Journal:  Microsc Res Tech       Date:  2003-06-15       Impact factor: 2.769

8.  Reduced CSF neurotensin concentration in drug-free schizophrenic patients.

Authors:  L H Lindström; E Widerlöv; G Bisette; C Nemeroff
Journal:  Schizophr Res       Date:  1988 Jan-Feb       Impact factor: 4.939

9.  Anorectic effect of calcitonin, neurotensin and bombesin infused in the area of the rostral part of the nucleus of the tractus solitarius in the rat.

Authors:  R de Beaurepaire; C Suaudeau
Journal:  Peptides       Date:  1988 Jul-Aug       Impact factor: 3.750

Review 10.  Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings.

Authors:  G W Dalack; D J Healy; J H Meador-Woodruff
Journal:  Am J Psychiatry       Date:  1998-11       Impact factor: 18.112
View more
  15 in total

1.  Cross-receptor interactions between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of dopaminergics.

Authors:  Susanne Koschatzky; Nuska Tschammer; Peter Gmeiner
Journal:  ACS Chem Neurosci       Date:  2011-04-11       Impact factor: 4.418

Review 2.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

Review 3.  NDE1 and NDEL1 from genes to (mal)functions: parallel but distinct roles impacting on neurodevelopmental disorders and psychiatric illness.

Authors:  Nicholas J Bradshaw; Mirian A F Hayashi
Journal:  Cell Mol Life Sci       Date:  2016-10-14       Impact factor: 9.261

4.  Neurotensin triggers dopamine D2 receptor desensitization through a protein kinase C and beta-arrestin1-dependent mechanism.

Authors:  Dominic Thibault; Paul R Albert; Graciela Pineyro; Louis-Éric Trudeau
Journal:  J Biol Chem       Date:  2011-01-13       Impact factor: 5.157

5.  Effects of neurotensin-2 receptor deletion on sensorimotor gating and locomotor activity.

Authors:  David Feifel; Zhen Pang; Zheng Pang; Paul D Shilling; Gilia Melendez; Rudy Schreiber; Donald Button
Journal:  Behav Brain Res       Date:  2010-04-21       Impact factor: 3.332

6.  The role of endogenous neurotensin in psychostimulant-induced disruption of prepulse inhibition and locomotion.

Authors:  Ricardo Cáceda; Elisabeth B Binder; Becky Kinkead; Charles B Nemeroff
Journal:  Schizophr Res       Date:  2011-11-21       Impact factor: 4.939

7.  Association between neurotensin receptor 1 (NTR1) gene polymorphisms and schizophrenia in a Han Chinese population.

Authors:  Hui Ma; Yinglin Huang; Bo Zhang; Jingying Li; Yuan Wang; Xiaofeng Zhao; Qiu Jin; Gang Zhu
Journal:  J Mol Neurosci       Date:  2013-03-13       Impact factor: 3.444

8.  The neurotensin-1 receptor agonist PD149163 blocks fear-potentiated startle.

Authors:  Paul D Shilling; David Feifel
Journal:  Pharmacol Biochem Behav       Date:  2008-10       Impact factor: 3.533

9.  NT79: A novel neurotensin analog with selective behavioral effects.

Authors:  Mona Boules; Yanqi Liang; Siobhan Briody; Tomofumi Miura; Irfan Fauq; Alfredo Oliveros; Mina Wilson; Shaheen Khaniyev; Katrina Williams; Zhimin Li; Yanfei Qi; Michael Katovich; Elliott Richelson
Journal:  Brain Res       Date:  2009-10-27       Impact factor: 3.252

10.  Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders.

Authors:  Sarah K Leonard; Jason M Dwyer; Stacey J Sukoff Rizzo; Brian Platt; Sheree F Logue; Sarah J Neal; Jessica E Malberg; Chad E Beyer; Lee E Schechter; Sharon Rosenzweig-Lipson; Robert H Ring
Journal:  Psychopharmacology (Berl)       Date:  2008-03-03       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.